The R&D centre will endeavour to bring scientifically advanced biological, biotechnology products and novel drug delivery systems
Flattish volume growth and subdued new launches were key factors for last month
With two maintenance doses a year, Leqvio is the first and only FDA-approved small interfering RNA (siRNA) therapy for LDL-C (bad cholesterol) reduction1
It is the first approved generic and is eligible for 180 days of Competitive Generic Therapy exclusivity
Deplesin is an add-on therapy to gold standard agents like lithium, valproic acid, and carbamazepine, supporting patients in ways that prescription medications often cannot
The group now has 325 approvals and has so far filed over 400 ANDAs since the commencement of the filing process in FY 2003-04.
Growing CRISPR genome editing portfolio supports researchers on path to future therapeutic applications
Contribution from the top five therapies stood at 58% of IPM in October 2021. These therapies are cardiac, anti-infectives, gastro-intestinal, anti-diabetic and vitamins
The drug helps in managing cholesterol
Acute therapies continue to report strong growth compared to chronic ones.
Subscribe To Our Newsletter & Stay Updated
